8.47
price up icon18.63%   1.33
after-market After Hours: 8.47
loading
Tango Therapeutics Inc stock is traded at $8.47, with a volume of 3.41M. It is up +18.63% in the last 24 hours and up +29.71% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$7.14
Open:
$7.25
24h Volume:
3.41M
Relative Volume:
1.72
Market Cap:
$942.37M
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-6.3684
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
+11.74%
1M Performance:
+29.71%
6M Performance:
+500.71%
1Y Performance:
+23.47%
1-Day Range:
Value
$7.25
$8.59
1-Week Range:
Value
$6.78
$8.59
52-Week Range:
Value
$1.03
$8.80

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name
Name
Tango Therapeutics Inc
Name
Phone
(857) 320-4900
Name
Address
201 BROOKLINE AVENUE, BOSTON
Name
Employee
155
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TNGX
Tango Therapeutics Inc
8.47 794.40M 24.30M -145.57M -149.17M -1.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.37 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.95 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
557.73 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
799.56 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
327.03 35.16B 4.56B -176.77M 225.30M -1.7177

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-19-25 Initiated Piper Sandler Overweight
Jul-17-24 Initiated Jefferies Buy
Apr-04-24 Initiated Cantor Fitzgerald Overweight
Feb-12-24 Initiated Piper Sandler Overweight
Dec-08-23 Initiated B. Riley Securities Buy
Oct-20-22 Upgrade H.C. Wainwright Neutral → Buy
Sep-20-21 Initiated SVB Leerink Outperform
View All

Tango Therapeutics Inc Stock (TNGX) Latest News

pulisher
12:01 PM

Multi asset correlation models including Tango Therapeutics Inc.2025 Price Action Summary & Risk Adjusted Buy/Sell Alerts - newser.com

12:01 PM
pulisher
10:45 AM

What earnings revisions data tells us about Tango Therapeutics Inc.Portfolio Performance Report & Free Accurate Trade Setup Notifications - newser.com

10:45 AM
pulisher
10:05 AM

Best data tools to analyze Tango Therapeutics Inc. stock2025 Price Momentum & Low Drawdown Momentum Trade Ideas - newser.com

10:05 AM
pulisher
09:41 AM

Detecting price anomalies in Tango Therapeutics Inc. with AIJuly 2025 PreEarnings & AI Enhanced Trade Execution Alerts - newser.com

09:41 AM
pulisher
09:08 AM

Developing predictive dashboards with Tango Therapeutics Inc. dataWeekly Stock Recap & Real-Time Volume Analysis - newser.com

09:08 AM
pulisher
08:56 AM

How to build a dashboard for Tango Therapeutics Inc. stockJuly 2025 Outlook & Consistent Profit Alerts - newser.com

08:56 AM
pulisher
02:17 AM

Is Tango Therapeutics Inc. stock entering bullish territoryJuly 2025 Chart Watch & Risk Adjusted Buy and Sell Alerts - newser.com

02:17 AM
pulisher
Oct 12, 2025

Tango Therapeutics Inc. stock trendline breakdownIPO Watch & Reliable Entry Point Alerts - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? - MSN

Oct 11, 2025
pulisher
Oct 10, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $10.50 Average PT from Analysts - Defense World

Oct 10, 2025
pulisher
Oct 10, 2025

Will Tango Therapeutics Inc. benefit from macro trendsChart Signals & Reliable Price Action Trade Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Is a relief rally coming for Tango Therapeutics Inc. holders2025 Market Overview & Fast Moving Trade Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Market reaction to Tango Therapeutics Inc.’s recent newsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Real time alert setup for Tango Therapeutics Inc. performance2025 Major Catalysts & Safe Capital Growth Plans - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Tango Therapeutics' (TNGX) Sell (E+) Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 09, 2025

Historical volatility pattern of Tango Therapeutics Inc. visualizedMarket Activity Summary & Fast Moving Market Watchlists - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Real time social sentiment graph for Tango Therapeutics Inc.Earnings Growth Summary & Daily Entry Point Trade Alerts - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Tango To Present At The 2025 SITC Annual Meeting — Will New Insights Make Waves? - RTTNews

Oct 09, 2025
pulisher
Oct 09, 2025

Regression analysis insights on Tango Therapeutics Inc. performanceTrade Ideas & Daily Oversold Bounce Ideas - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is Tango Therapeutics Inc. building a consolidation base2025 Major Catalysts & Breakout Confirmation Trade Signals - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials By Investing.com - Investing.com South Africa

Oct 08, 2025
pulisher
Oct 08, 2025

Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials - Investing.com UK

Oct 08, 2025
pulisher
Oct 06, 2025

Tango Therapeutics to Present First Clinical Data from - GlobeNewswire

Oct 06, 2025
pulisher
Oct 06, 2025

First clinical data: TNG260 — Tango Therapeutics presents Phase 1/2 results at SITC Nov 7 - Stock Titan

Oct 06, 2025
pulisher
Oct 05, 2025

Building trade automation scripts for Tango Therapeutics Inc.Weekly Stock Analysis & Daily Growth Stock Investment Tips - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 03:22:51 - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Piper Sandler Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $11 - 富途牛牛

Oct 03, 2025
pulisher
Oct 03, 2025

Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com

Oct 03, 2025
pulisher
Oct 03, 2025

Multi factor analysis applied to Tango Therapeutics Inc.Bull Run & Fast Momentum Entry Tips - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

How to use Fibonacci retracement on Tango Therapeutics Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com

Oct 02, 2025
pulisher
Oct 01, 2025

Tango Therapeutics Hits New 52-Week High of $8.79, Marking Major Milestone - Markets Mojo

Oct 01, 2025
pulisher
Oct 01, 2025

Healthcare veteran David Wilkinson to join Tango as chief financial officer - MarketScreener

Oct 01, 2025
pulisher
Sep 30, 2025

Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN

Sep 30, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 04:30:06 - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Published on: 2025-09-30 03:51:20 - newser.com

Sep 30, 2025
pulisher
Sep 29, 2025

Major Shareholder Sells Off Tango Therapeutics Stock in Multi-Million Dollar Deal! - TipRanks

Sep 29, 2025
pulisher
Sep 29, 2025

Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 500,000 Shares - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Tango Therapeutics, Inc. $TNGX Position Reduced by Goldman Sachs Group Inc. - Defense World

Sep 29, 2025
pulisher
Sep 29, 2025

Tango Therapeutics Hits New 52-Week High at $8.56 - Markets Mojo

Sep 29, 2025

Tango Therapeutics Inc Stock (TNGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$84.73
price up icon 1.11%
$22.93
price up icon 7.40%
$32.68
price up icon 2.73%
$102.30
price up icon 0.24%
$163.94
price up icon 0.99%
biotechnology ONC
$327.03
price up icon 2.16%
Cap:     |  Volume (24h):